Symbols

AGIO

Agios·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AGIO

Agios Pharmaceuticals, Inc.

A leader in the field of cellular metabolism to treat rare and genetically defined diseases

Industry

Biological Technology

Established Date

08/07/2007

Listing Date

07/24/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

486

Fiscal Year Ends

12-31

Website

www.agios.com

Security Type

Common stock

Office address

88 Sidney Street, Cambridge, MA 02139

Business

Introduction

Agios Pharmaceuticals, Inc., was incorporated in Delaware on August 7, 2007. The company is a biopharmaceutical company dedicated to transforming patients' lives through leadership in cell metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology.

Earnings Call

Q1/2025

Estimate EPS-1.76

Actual EPS-1.55

Estimate Revenue9.68M

Actual Revenue8.70M

Agios Pharmaceuticals' Q1 2025: Dissecting Key Contradictions in FDA Engagement, Tebapivat Development, and Pricing Strategies

May 02,2025 07:28·
Earnings Decrypt

Q2/2025

Estimate EPS-1.78

Actual EPS-1.93

Estimate Revenue9.52M

Actual Revenue12.45M

Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy

Aug 02,2025 06:15·
Earnings Decrypt

Company Financials

EPS

AGIO has released its 2025 Q3 earnings. EPS was reported at -1.78, versus the expected -1.9, beating expectations. The chart below visualizes how AGIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AGIO has released its 2025 Q3 earnings report, with revenue of 12.88M, reflecting a YoY change of 43.69%, and net profit of -103.43M, showing a YoY change of -110.91%. The Sankey diagram below clearly presents AGIO's revenue sources and cost distribution.